Needham Reiterates Buy on Cara Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Cara Therapeutics (NASDAQ:CARA) and maintained a $5 price target.
April 10, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Cara Therapeutics with a $5 price target.
The reiteration of a Buy rating by a reputable analyst like Joseph Stringer, along with maintaining a $5 price target, signals continued confidence in Cara Therapeutics' potential. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in CARA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100